Evolus investors frown as FDA declines to approve Botox rival
Read More
Bagikan Berita Ini
Rabu, 16 Mei 2018
News Business
Evolus investors frown as FDA declines to approve Botox rival
(Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.
Evolus investors frown as FDA declines to approve Botox rival
Read More
Bagikan Berita Ini
Evolus investors frown as FDA declines to approve Botox rival
Read More
Bagikan Berita Ini
0 Response to "Evolus investors frown as FDA declines to approve Botox rival"
Posting Komentar